Recently, Gao Huimin, Deputy Director of the Boao Lecheng International Medical Tourism Pilot Zone Administration , and Zhou Lianghui, General Manager of Hainan Boao Lecheng Development Holding Co., Ltd., led a delegation to Deep Harbour Cell Valley for an exchange visit. The theme of this exchange was "Deepening Cooperation in the Field of Cell Therapy and Exploring New Pathways for Industry Development," aiming to promote in-depth collaboration between the two sides in medical technology innovation, industrial synergy, and policy implementation. It also sought to jointly explore new pathways for coordinated development in the field of cell therapy between the Guangdong-Hong Kong-Macao Greater Bay Area and the Hainan Free Trade Port, thereby enhancing the influence of China's cell therapy on the international stage. Accompanied by Professor Shi Yuanyuan, founder of Deep Harbour Cell Valley, the visiting delegation toured the Smart Exhibition Hall, Multi-Regional Collaborative Laboratory, and GMP Industrial Production Platform. They gained in-depth insights into the latest advancements in cutting-edge cell and gene therapy technologies, breakthroughs in core technologies, and resource integration practices between Shenzhen and Hong Kong. Leaders from the Lecheng Administrative Bureau highly commended Cell Valley's achievements in innovative drug development, clinical translation, and international cooperation. The delegation engaged in in-depth discussions on synergistic mechanisms between Lecheng's policy advantages and Cell Valley's technological strengths, product quality control system development, and technology transfer pathways. During the symposium, Professor Shi warmly welcomed the delegation from Lecheng Administrative Bureau and Lecheng Holdings, systematically outlining Cell Valley's development roadmap and phased achievements. He emphasized that as the first enterprise in Guangdong Free Trade Zone to benefit from national medical openness pilot policies, Deep Harbour Cell Valley has consistently focused on full-chain innovation in cell therapy, establishing a complete system covering "basic research—technological breakthroughs—clinical translation—industrial production." As China's "test bed" for policy breakthroughs in cell therapy, Lecheng Pilot Zone has gained first-mover advantages in policy innovation, international resource aggregation, and industrial transformation. Looking ahead, Cell Valley is committed to leveraging its international expertise in cell product quality control and core technologies to actively support Lecheng in building a national pioneer hub for cell therapy innovation. Deputy Director Gao Huimin highlighted the achievements of Lecheng Pilot Zone in core policies including "import of licensed pharmaceuticals and medical devices," "real-world data application," and "biomedical new technologies." He noted that the technological expertise of Deep Harbour Cell Valley and Lecheng's policy advantages are highly complementary. He expressed hope for pragmatic cooperation between both parties in clinical research of cell therapy products, cross-border applications, and upstream-downstream collaboration, aiming to accelerate the translation of technological achievements and benefit more patients. General Manager Zhou Lianghui elaborated on the latest progress of Lecheng Development Holdings in establishing the Boao Cell Therapy Public Service Center, focusing on the synergy between industrial infrastructure and capital investment. He emphasized that Lecheng is accelerating the development of an integrated service platform encompassing R&D, production, and quality control to facilitate efficient implementation of healthcare projects. Looking ahead, the company aims to strengthen collaboration with Deep Harbour Cell Valley in regional coordination, resource sharing, and innovative project execution, with the shared goal of creating a cross-regional industrial synergy benchmark. Both sides agreed to take this exchange as an opportunity to further strengthen strategic coordination, fully leverage the synergistic effects of policy innovation and technological breakthroughs, and deepen cooperation in cutting-edge technology R&D, clinical application transformation, and international resource integration, jointly driving China's medical technology innovation and industrialization to achieve leapfrog development.